Philips piles on another trio of Class I recalls for beleaguered ventilator portfolio Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst CMS proposes acute hospitals get 3.2% pay bump in 2023, calls for equity quality measures Moderna's bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabs Digital twin generator Unlearn nets $50M to bolster clinical trials with AI models Gilead targets 400 jobs, assembles cell therapy manufacturing troika with FDA nod for Maryland site Former CMS administrator resigns from Centene board after governance 'fell egregiously short' Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition Axonics kicks off U.S. launch of recharge-free sacral neuromodulation implant Johnson & Johnson, after weak quarter of vaccine sales, will no longer include it in guidance Supreme Court nixes appeal on Arkansas' Medicaid work requirements program Finch's nest thins out with 20% of employees cut in restructuring after FDA hold Featured Story | By Andrea Park There seems to be no limit to Philips’ ventilator safety woes. Nearly a full year after initiating a recall of 5.2 million respiratory devices, the company continues to accumulate safety notices for those and other devices in its vast respiratory portfolio. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax's program could be destined to reap billions of dollars in sales this year, one group of analysts predicts. read more By Robert King CMS is proposing acute care hospitals get a 3.2% bump to payments for fiscal year 2023 and seeks to add three new quality reporting measures focused on health equity. read more By Nick Paul Taylor Moderna’s bivalent COVID-19 vaccine has bettered the antibody response of Spikevax against omicron when given as a booster, offering encouragement to the biotech as it races toward phase 2/3 data that will shape its offering for the next season of jabs. read more By Conor Hale The goal is to help drugmakers and academic researchers complete clinical trials while requiring fewer overall participants. read more By Angus Liu Gilead Sciences’ Kite Pharma has further beefed up its cell therapy manufacturing footprint as a recent FDA approval for Yescarta promises to increase demand. read more By Rebecca Torrence Leslie Norwalk, a former Centers for Medicare & Medicaid Services administrator appointed just months ago to the Centene board of directors, has resigned from the board after citing her dissatisfaction with the insurer's governance process and approach to leadership. read more By James Waldron Regeneron has shown there is more to skin cancer drugs than PD-1 inhibitors through its $250 million acquisition of Checkmate Pharmaceuticals and its lead immuno-oncology asset vidutolimod. read more By Andrea Park Barely a month after winning FDA clearance for its long-lasting device to treat bladder dysfunction, Axonics is wasting no time in bringing it to the masses. read more By Kevin Dunleavy After a disappointing quarter of sales for its COVID-19 vaccine, Johnson & Johnson will no longer include the vaccine in its revenue projections. J&J reported sales of the vaccine for the first quarter at $457 million, far off from Wall Street’s estimate of $785 million. The company also has reduced its overall revenue projection for the year. read more By Robert King The Supreme Court has nixed an appeal to a case that struck down HHS' Medicaid work requirements, more than a year after oral arguments on the case were cancelled. read more By Annalee Armstrong Finch Therapeutics’ nest is getting a bit smaller. Some 20% of the company's workforce is being let go amid a restructuring spurred by an FDA clinical hold and the pausing of a chronic hepatitis B program. read more |
